title: Macro-economic factors influencing the architectural business model shift in the pharmaceutical industry.
abstract: Technological innovations, new regulations, increasing costs of drug productions and new demands are only few key drivers of a projected alternation in the pharmaceutical industry. The purpose of this review is to understand the macro economic factors responsible for the business model revolution to possess a competitive advantage over market players. Areas covered: Existing literature on macro-economic factors changing the pharmaceutical landscape has been reviewed to present a clear image of the current market environment. Expert commentary: Literature shows that pharmaceutical companies are facing an architectural alteration, however the evidence on the rationale driving the transformation is outstanding. Merger & Acquisitions (M&A) deals and collaborations are headlining the papers. Q1 2016 did show a major slowdown in M&A deals by volume since 2013 (with deal cancellations of Pfizer and Allergan, or the downfall of Valeant), but pharmaceutical analysts remain confident that this shortfall was a consequence of the equity market volatility. It seems likely that the shift to an M&A model will become apparent during the remainder of 2016, with deal announcements of Abbott Laboratories, AbbVie and Sanofi worth USD 45billion showing the appetite of big pharma companies to shift from the fully vertical integrated business model to more horizontal business models.
authors.affiliation: a Department of Public Health, Faculty of Medicine, Epidemiology and Health Economics , Université de Liège , Liège , Belgium.
authors.forename: Raphaela Marie Louisa
authors.initials: RM
authors.lastname: Dierks
authors.affiliation: a Department of Public Health, Faculty of Medicine, Epidemiology and Health Economics , Université de Liège , Liège , Belgium.
authors.forename: Olivier
authors.initials: O
authors.lastname: Bruyère
authors.affiliation: a Department of Public Health, Faculty of Medicine, Epidemiology and Health Economics , Université de Liège , Liège , Belgium.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Reginster
authors.affiliation: a Department of Public Health, Faculty of Medicine, Epidemiology and Health Economics , Université de Liège , Liège , Belgium.
authors.forename: Florent-Frederic
authors.initials: FF
authors.lastname: Richy
mesh_terms: D003132:Commerce / Q000191:economics / Q000458:organization & administration*; D003299:Cooperative Behavior; D004345:Drug Industry / Q000191:economics / Q000458:organization & administration*; D004465:Economic Competition; D006801:Humans; D017146:Models, Organizational
keywords: Macro-economic factors; business model; healthcare; pharmaceutical industry